The Medicinal Chemistry of Peptides

被引:107
|
作者
Nestor, J. J., Jr. [1 ]
机构
[1] EuMederis Pharmaceut Inc, Encinitas, CA 92024 USA
关键词
Peptide; peptide design; peptide pharmaceutical; drug design; medicinal chemistry; constrained peptide; pharmacodynamics; pharmacokinetics; drug depot; GLUCAGON-LIKE PEPTIDE-1; HUMAN GROWTH-HORMONE; CATALYTIC ASYMMETRIC-SYNTHESIS; BIOLOGICALLY-ACTIVE PEPTIDES; CONSTRAINED AMINO-ACIDS; IN-VIVO; ALBUMIN-BINDING; REVERSIBLE LIPIDIZATION; COMPETITIVE ANTAGONISTS; CONFORMATIONAL-ANALYSIS;
D O I
10.2174/092986709789712907
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The shortcomings of native peptides as pharmaceuticals have been long known: short duration of action, lack of receptor selectivity, lack of oral bioavailability. However medicinal chemistry offers solutions to the first two limitations and oral bioavailability issues have been addressed with novel routes of administration (e. g. intranasal, inhalation) and injectable depot formulations. The principal issue for peptide drugs has been a short duration of action, widely assumed to be due to proteolysis. While proteolysis is a problem for native peptide structures, modification of the peptide structure by acylation, PEGylation, unnatural amino acids or restricted conformation can largely remove this issue. However rapid clearance from the blood into the urine remains an issue for even proteolytically stable molecules. Medicinal chemistry approaches here have been peptide modifications to slow release from the injection site (hydrophobic, hydrophilic, self-associating depots), PEGylation, fatty acid acylation, and the like. Medicinal chemistry approaches used in successful peptide pharmaceuticals using unnatural amino acids to achieve depot formation are highlighted in this review.
引用
收藏
页码:4399 / 4418
页数:20
相关论文
共 50 条
  • [41] Medicinal chemistry for 2020
    Satyanarayanajois, Seetharama D.
    Hill, Ronald A.
    FUTURE MEDICINAL CHEMISTRY, 2011, 3 (14) : 1765 - 1786
  • [42] Fluorine in medicinal chemistry
    Purser, Sophie
    Moore, Peter R.
    Swallow, Steve
    Gouverneur, Veronique
    CHEMICAL SOCIETY REVIEWS, 2008, 37 (02) : 320 - 330
  • [43] PROGRESS IN MEDICINAL CHEMISTRY
    HODGE, HC
    JOURNAL OF THE AMERICAN DENTAL ASSOCIATION, 1965, 71 (03): : 735 - &
  • [44] Proteomics in medicinal chemistry
    Niwayama, S
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2006, 6 (02) : 241 - 246
  • [45] Open Medicinal Chemistry
    Peralta, David
    CHEMMEDCHEM, 2019, 14 (01) : 4 - 7
  • [46] The Medicinal Chemistry of Caffeine
    Faudone, Giuseppe
    Arifi, Silvia
    Merk, Daniel
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (11) : 7156 - 7178
  • [47] Medicinal chemistry scholarships
    Houlihan, B
    CHEMICAL & ENGINEERING NEWS, 2003, 81 (21) : 4 - 4
  • [48] NMR in medicinal chemistry
    Kessler, H
    Heller, M
    Gemmecker, G
    Diercks, T
    Planker, E
    Coles, M
    SMALL MOLECULE-PROTEIN INTERACTIONS, 2003, 42 : 59 - 85
  • [49] Fluorine in medicinal chemistry
    Böhm, HJ
    Banner, D
    Bendels, S
    Kansy, M
    Kuhn, B
    Müller, K
    Obst-Sander, U
    Stahl, M
    CHEMBIOCHEM, 2004, 5 (05) : 637 - 643
  • [50] Epigenetic Medicinal Chemistry
    Copeland, Robert A.
    ACS MEDICINAL CHEMISTRY LETTERS, 2016, 7 (02): : 124 - 127